Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC
1 day ago · The FDA has accepted a supplemental new drug application (sNDA) seeking expanded indication for darolutamide (Nubeqa) for use in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Data from the phase 3 ARANOTE ...
Clinical Focus - Targeted Oncology
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Less Toxic, More Personalized Treatments on the Horizon in …
Sep 12, 2024 · Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.
Targeted Therapies in Oncology - Targeted Oncology
Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with its meeting coverage, columns, FDA news, and more. Click Here to Subscribe
Breast Cancer | Oncology News & Insights - Targeted Oncology
November 13th 2024. During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Prostate Cancer - Targeted Oncology
October 14th 2024. The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately 220 patients with prostate cancer with biochemical recurrence.
Pimicotinib Shows Promising Efficacy and Tolerability in TGCT
2 days ago · Pimicotinib (ABSK021) led to an objective response rate (ORR) at week 25 of 54.0% in patients with tenosynovial giant cell tumor (TGCT) vs 3.2% for placebo (P <.0001) based on RECIST v1.1 per Blinded Independent Review Committee (BIRC), meeting the primary end point of the phase 3 MANEUVER study (NCT05804045). 1The study also demonstrated statistically significant and clinically meaningful ...
Melanoma - Targeted Oncology
October 10th 2024. During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Bladder Cancer - Targeted Oncology
October 28th 2024. TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.